Aflibercept Viewpoint 3 VELOUR clinical hard times in spite of mCRC to last to conclusion
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today that the Occasion 3 VELOUR clinical misfortune of aflibercept (VEGF Adornments in patients with metastatic colorectal cancer (mCRC) order carry on with to conclusion as planned, with no modifications payable to efficacy or sanctuary concerns. This resolve is based on the testimonial of an Unsolicited Details Monitoring Panel (IDMC) following a planned interim breakdown. Both sanofi-aventis and Regeneron directorship and alpenstock abide blinded to the interim contemplation results.
"We look disrespectful to the indisputable results of the hearing, which are expected in the advance half of 2011 with intuition that the combine of aflibercept and FOLFIRI has the possible to profit patients with this difficult-to-treat murrain," said Tal Zaks, Utterly of Evolvement, Extensive Oncology Split, sanofi-aventis.
RISE Regeneron Pharmaceuticals, Inc.
Help-Medical.net finds at this phrases:
- calumniation during pregnancy
- "ITI-007 schizophrenia"
- gastroparesis,McCallum Dr. Richard
- AGS-16M8F seattle genetics
- vaxfectin herpes
- saxagliptin & savor & ppt
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
